Table I.
IC50 data for growth inhibition of cancer cells by doxorubicin and doxazolidine. Cells were treated with drug for 3 h and growth was measured when controls reached 80% confluence.
| log IC50 (M) | |||
|---|---|---|---|
| Cell Line | Cancer Type | Doxorubicin | Doxazolidine |
| SHP-77 | S. Cell Lung | > −6.0 | −8.7 ± 0.07 |
| A375 | Melanoma | −6.7 ± 0.04 | −9.0 ± 0.02 |
| PC-3 | Prostate | −6.5 ± 0.14 | −8.0 ± 0.15 |
| DU-145 | Prostate | −6.6 ± 0.0744 | −8.5 ± 0.0744 |
| LNCaP | Prostate | −7.6 ± 0.0644 | −8.9± 0.0644 |
| MCF-7 | Breast | −6.543 | −8.5 ± 0.0343 |
| MCF-7/ADR | Breast | −5.2 ± 0.143 | −9.020 |
| MDA-MB-435 | Breast | −6.8 ± 0.745 | −8.0 ± 0.02 |
| Hep G2 | Liver | −6.7 ± 0.0943 | −8.0 ± 0.0843 |
| SK-HEP-1 | Liver | −7.0 ± 0.143 | −8.4 ± 0.143 |
| MiaPaCa-2 | Pancreas | −6.5 ± 0.09 | −8.5 ± 0.08 |
| BxPC-3 | Pancreas | −6.5 ± 0.14 | −8.0 ± 0.15 |
| HeLaS3 | Cervix | −7.424 | −8.524 |
| Mean | > −6.6 ± 0.14 | −8.5 ± 0.15a | |
| H9c2(2-1) | Heart | −7.5 ± 0.243 | −7.5 ± 0.243 |
a
p<0.000005 in comparison with doxorubicin.